Without a US FDA-approved RET CDx, not only will potential RET inhibitors not gain US FDA approval to treat RET-rearranged NSCLC but other RET-rearranged malignancies such as thyroid cancer (19) or chronic myelomonocytic leukemia (CMML) (29). This evidence concerns the gene RET and thyroid cancer.